BioCentury | Jul 25, 2019
Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

...ARG1 - arginase 1; CEP290 - centrosomal protein 290kDa; NOX1 - NADPH oxidase 1; NOX4 - NADPH oxidase...
BioCentury | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

...pore; NFE2L2 (NRF2) - Nuclear factor (erythroid-derived 2)-like 2; NOX1 - NADPH oxidase 1; NOX4 - NADPH oxidase...
BioCentury | May 2, 2019
Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

...furoate/vilanterol/umeclidinium, fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI (GSK2834425) Biogen Inc. bluebird bio Inc. Celgene Corp. Genkyotex S.A. GlaxoSmithKline plc Innoviva Inc. Ionis Pharmaceuticals Inc. NADPH oxidase 1 (NOX1) NADPH oxidase...
BioCentury | Apr 15, 2019
Distillery Therapeutics

Inhibiting NOX2 or FOXC1 to treat AML and CML

...steps could include identifying and testing inhibitors of NOX2 and FOXC1 in the models. TARGET/MARKER/PATHWAY: NADPH oxidase...
...Craig T. Jordan, University of Colorado, Aurora, Colo. email: craig.jordan@ucdenver.edu Claire Quang University of Colorado Forkhead box C1 (FOXC1) NADPH oxidase...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...the cancer metabolism scene, emerging metabolic targets at AACR 2019 include enzymes controlling oxidation. The NADPH oxidase...
...2 mTORC1 - Mammalian target of rapamycin complex 1 NOX1 - NADPH oxidase 1 NOX4 - NADPH oxidase...
...Inc. MiNA Therapeutics Ltd. c-Mer proto-oncogene tyrosine kinase (MERTK) Chemokine CC motif ligand 21 (CCL21) Musashi RNA-binding protein 1 (MSI1) NADPH oxidase...
BioCentury | Nov 9, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

...Elias Papatheodorou told BioCentury that Genkyotex hopes to start Phase III testing of the dual NADPH oxidase...
...treat idiopathic pulmonary fibrosis. Genkyotex S.A. (Euronext:GKTX), Saint-Julien-en-Genevois, France Product: GKT831 Business: Hepatic Molecular target: NADPH oxidase...
...Status: Interim Phase II data Milestone: Additional Phase II data (1H19) Jennie Walters GKT831, gkt137831 Genkyotex S.A. NADPH oxidase 1 (NOX1) NADPH oxidase...
BioCentury | Nov 5, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

...Elias Papatheodorou told BioCentury that Genkyotex hopes to start Phase III testing of the dual NADPH oxidase...
...gained €0.12 to €1.60 on Monday. Intercept added $0.58 to $110.13. Jennie Walters GKT831, gkt137831 Genkyotex S.A. NADPH oxidase 1 (NOX1) NADPH oxidase...
BioCentury | Aug 22, 2017
Distillery Therapeutics

Cancer

...non-alcoholic steatohepatitis (NASH) and diabetic nephropathy and preclinical testing for liver and pulmonary fibrosis. TARGET/MARKER/PATHWAY: NADPH oxidase...
...3, 2017 doi:10.1093/jnci/djx121 CONTACT: Gareth Thomas, University of Southampton, Southampton, U.K. email: g.thomas@soton.ac.uk Elizabeth S. Eaton GKT831 Genkyotex S.A. NADPH oxidase...
BioCentury | Aug 8, 2017
Preclinical News

Researchers suggest inhibiting NOX4 could treat cancer

...of the National Cancer Institute , researchers at the University of Southampton showed that inhibiting NADPH oxidase...
...is evaluating GKT831 in Phase II testing to treat primary biliary cholangitis (PBC). Elizabeth S. Eaton GKT137831 Genkyotex S.A. NADPH oxidase...
BioCentury | Jul 3, 2017
Clinical News

Genkyotex begins Phase II of GKT831 in PBC

...data from the trial in 1H18 and full results in 2H18. GKT831 is a dual NADPH oxidase...
...NOX4 inhibitor. Genkyotex S.A. (Euronext:GKTX), Plan-les-Ouates, Switzerland Product: GKT831 (formerly GKT137831) Business: Hepatic Molecular target: NADPH oxidase...
...II started Milestone: Interim Phase II data (1H18); Phase II data (2H18) Julian Zhu GKT831 Genkyotex S.A. NADPH oxidase 1 (NOX1) NADPH oxidase...
Items per page:
1 - 10 of 61